AI-powered contentSome parts of this article are powered by AI.
Share this article
Gotrade News - Arcturus Therapeutics (Nasdaq: ARCT) on Monday, November 16, 2026, announced an expanded collaboration with Meiji Seika Pharma Co., Ltd. that includes a $50 million equity investment at an 80% premium, with Meiji paying $20.27 per share, according to Arcturus' official release.
Regular-session close on November 16, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Market cap: that close times the shares outstanding on the latest 10-Q or 10-K cover (SEC EDGAR).
What Arcturus Announced
Under the securities purchase agreement, Meiji will purchase $50 million of unregistered Arcturus securities at $20.27 per share, which the release says is 7.9% of the outstanding shares of Arcturus after the transaction. According to the company's Form 8-K, Arcturus sold Meiji 2,466,395 shares, the closing occurred concurrently with the signing, and the price represents a premium of 80% to the average closing price of the common stock over the 30 trading days through and including November 11, 2026.
Alongside the investment, the two companies entered into an exclusive license agreement relating to the application of Arcturus' ARCT-154 technology for an undisclosed therapeutic area, under which, the filing states, Meiji will be responsible for development and commercialization at its cost. They also signed a memorandum of understanding (MOU) setting out the principal terms for a potential collaboration and license agreement for a pandemic preparedness and response program in Japan using the Arcturus platform. The filing states that neither party is obligated to enter into that definitive agreement.
Meiji agreed not to sell or transfer the shares through the 365th day following the date of the purchase agreement, and to standstill provisions for 24 months following the closing, according to the filing.
Why It Matters for ARCT
"Alongside our CF program, these proceeds will be used to accelerate development of ARCT-2601 for OTC deficiency, the first mRNA therapeutic to utilize our LUNAR 2.0 delivery platform," said Joseph Payne, President and Chief Executive Officer of Arcturus. The company said the proceeds are also meant to clinically validate its LUNAR 2.0 next-generation mRNA platform. Payne said the investment, the license agreement and the MOU "reflects Meiji's confidence in our development capabilities and the potential of our technology platform."
The Form 8-K adds a condition tied to the MOU: if Arcturus and Meiji do not enter into the definitive license agreement it contemplates by May 31, 2027, Arcturus is required to refund Meiji 50% of the premium, or approximately $11.1 million, in cash or, at the company's election and subject to certain limitations, in shares of common stock.
What to watch next: If Arcturus and Meiji do not enter into the definitive license agreement contemplated by the MOU by Monday, May 31, 2027, Arcturus is required to refund Meiji 50% of the premium, or approximately $11.1 million, according to the company's Form 8-K.
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
This article was written with the help of AI and checked by the Gotrade team before publishing.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.